Genetically modified probiotics for oral delivery of renin-angiotensin related therapeutic proteins and peptides
OwnerQiuhong LI, Mohan RAIZADAinventors
Life of this patent
Estimating the term…
Abstract
Provided herein are probiotic compositions that enable efficient, cost-effective and patient friendly oral therapeutics for treating diverse pathological conditions that involve the renin-angiotensin system (RAS), e.g., pulmonary hypertension, diabetes, diabetic complications, cardiovascular diseases, and ocular inflammatory and neurodegenerative diseases.
Claims6
A method of treating a disease or condition involving the RAS, the method comprising administering orally to a subject in need thereof a therapeutically effective dose of a probiotic composition comprising either genetically modified bacteria expressing Ang-(1-7) or genetically modified bacteria expressing ACE2, or both;
- wherein the genetically modified bacteria expressing Ang-(1-7) and/or ACE2 are a Lactobacillus sp.;
- and wherein the probiotic composition comprises a Lactobacillus-milk suspension formed by combining lyophilized genetically modified Lactobacillus sp. expressing Ang-(1-7) and/or lyophilized genetically modified Lactobacillus sp. expressing ACE2 with milk.
A Lactobacillus-milk suspension formed by combining lyophilized genetically modified Lactobacillus sp. expressing Ang-(1-7) and/or lyophilized genetically modified Lactobacillus sp. expressing ACE2 with milk.
Dependencies are inferred from the claim text.